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Abstract
Background: Hodgkin lymphoma is a systemic disease that commonly involves the cervical, supraclavicular, and
mediastinal lymph nodes. The involvement of central nervous system in Hodgkin lymphoma is extremely rare, and
diagnosis is usually established using distinct morphological and immunohistochemical staining on the tissue biopsied. Extranodal presentation of HL is a rare occurrence. It has been evident that prognosis is encouraging in patients
with disease that is limited to just central nervous system initially or as relapse, compared with involvement of multiple sites of relapse.
Case presentation: We herein report a case of a 35-year-old South-East Asian male with relapsed Hodgkin lymphoma. The patient developed a parotid gland lesion, cervical lymphadenopathy with significant weight loss, and
intermittent night sweats. Along with spread to the central nervous system, there was a high suspicion of tuberculosis. Upon biopsy of his cervical lymph node, the patient was confirmed to have Hodgkin lymphoma. Immediate treatment began with six cycles of chemotherapy consisting of adriamycin, bleomycin, vinblastine, and dacarbazine. The
patient received three cycles of chemotherapy consisting of ifosfamide, carboplatin, and etoposide but then was lost
to follow-up. Five years later, the patient suffered a road traffic accident. Upon work-up, a right parietal space-occupying lesion with moderate cerebral edema and midline shift was found on computed tomography of the brain. The
patient underwent resection of the space-occupying lesion of brain, with features consistent with classical Hodgkin
lymphoma on histopathology examination. It is crucial for such lesions to be investigated meticulously to rule out any
secondary disease process.
Conclusion: Relapsed Hodgkin lymphoma with central nervous system involvement is relatively rare with just over
two dozen cases reported to date and is observed infrequently in developing nations. Therefore, space-occupying
lesion should always be investigated, and biopsy of such lesions is gold standard to establish diagnosis. With timely
appropriate therapy, complete remission can be achieved. However, large-scale studies would be prudent to explore
the presentation, survival, and treatment options for patients with Hodgkin lymphoma involving the central nervous
system.
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Background
Classic Hodgkin lymphoma (HL) is a cancer of the lymphatic system and primarily affects lymph nodes. As
compared with non-Hodgkin lymphoma (NHL), central
nervous system (CNS) involvement in HL is extremely
rare, recently shown to occur in less than 0.2–0.5% of
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HL patients [1] whereas CNS involvement can be found
in up to 5–30% of NHL patients [2]. Nodular sclerosis
and mixed cellularity are the most commonly seen histological subtypes of HL that occur in relapsed disease.
Treatment modalities include radiotherapy alone or in
combination with chemotherapy. We describe a patient
with classic HL presenting with relapse of disease in
the brain. The rare occurrence and paucity of available reports on such presentation make it a challenging
diagnosis for physicians. Moreover, these presentations
can prove to be a puzzling conundrum for physicians in
low-middle-income countries where timely diagnosis
and management can relieve the existing burden on the
under-resourced healthcare.

Case presentation
A 35-year-old South-East Asian male, nonsmoker, with
no known comorbidities, reported to outpatient facility
in 2012, when he developed right parotid swelling and
was managed conservatively. His swelling later transformed into an ulceration. He took multiple courses of
antibiotics prescribed by general physicians and also used
medication given by unqualified practitioners . Family
history was negative for any malignancies. The patient
belonged to a household of low socioeconomic status,
being employed as a domestic worker. In a few months’
time, the patient developed progressive cervical lymphadenopathy with significant weight loss and intermittent night sweats. Due to high prevalence of tuberculosis
in the local population, the patient underwent antituberculosis treatment (ATT) consisting of rifampicin (10 mg/
kg), isoniazid (5 mg/kg), ethambutol (15 mg/kg), and
pyrazinamide (25 mg/kg). However, no signs of improvement were observed after treatment for 2 months. During this time period, he developed an ulcerated lesion of
the right parotid gland. Biopsy of the cervical lymph node
revealed Hodgkin lymphoma, and the patient underwent
six cycles of chemotherapy ABVD [adriamycin (25 mg/
m2 intravenous), bleomycin (10 U/m2 intravenous), vinblastine (6 mg/m2 intravenous), and dacarbazine (DTIC)
(375 mg/m2 intravenous)]. Each cycle was repeated every
28 days, and this combination was administered on day 1
and day 15. No significant reduction in size of the lymph
nodes was observed after chemotherapy, and his parotid
gland lesion remained unchanged. Later in June 2013,
a biopsy of the ulcerated parotid gland lesion was performed with findings that were consistent with Hodgkin
lymphoma. He received his second-line chemotherapy:
three cycles of dexamethasone, high-dose Ara-C, and
platinol (DHAP). Staging computed tomography (CT)
was performed to evaluate the response of treatment,
which showed no interval change in parotid lesion but a
significant reduction in the size of cervical lymph nodes.
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Furthermore, 25 fractions of radiation therapy were
administered to the patient at the right side of his face
including right side of neck. After 10 months of treatment, disease progression was still observed with complaint of cervical lymphadenopathy. In 2014, the patient
received three cycles of chemotherapy consisting of ifosfamide, carboplatin, and etoposide (ICE). The patient
demonstrated noncompliance to further treatment
options and regular hospital visits because of financial
constraints, and was eventually lost to follow-up.
In 2019, the patient suffered a road traffic accident
(RTA) after 5 years of disease. The cause of RTA was
identified as loss of consciousness (LOC) as confirmed by
the patient’s brother, who was with him during the accident. A right parietal well-circumscribed space-occupying lesion of around 6.7 × 4.9 cm with moderate cerebral
edema and midline shift was found on CT brain imaging
as shown in Fig. 1. He regained his consciousness spontaneously after a few hours in the emergency department.
On further questioning, the patient described intermittent mild headaches a few months prior to the accident.
His general physical examination was normal, with few
marks of skin abrasions on his limbs. His lab workup
was also unremarkable. He was scheduled for elective
surgery and eventually underwent a gross total resection of the space-occupying lesion of brain. The specimen was sent for analysis, and immunohistochemistry
revealed atypical cell infiltrates largely positive for CD30,
CD15, and weakly positive PAX5 but lack of expression
for LCA, CD20, and CD3 as shown in Fig. 2. Surprisingly,
these features were consistent with classical Hodgkin
lymphoma according to the World Health Organization
(WHO) classification of lymphoid neoplasm. The patient
was reported to be alive and recovering well post-surgery during hospital follow-ups and was also advised to
see medical oncology for further cancer treatment. His
parotid gland ulceration responded to radiation therapy and very much regressed when he presented with
lymphadenopathy for the third time and received three
cycles of ICE. Unfortunately, he never showed up and
died after 4 months of his surgery, likely due to untreated
underlying cancer. Informed consent was obtained from
the patient’s uncle for the use of images and details for
reporting the case for publication and teaching purposes.

Discussion
Central nervous system involvement is rare with HL,
accounting for 0.2–0.5% of all cases [1], and mostly
occurs as a relapse. Due to the rare occurrence, only
22 cases to date have been reported in the literature [1,
3–5]. In contrast, CNS involvement is 5–30% in patients
with NHL [2]. Classical HL primarily affects the lymph
nodes as neurological sequelae rarely occur. However,

Ahmed et al. J Med Case Reports

(2021) 15:532

Page 3 of 5

Fig. 1 Radiographical presentation showing space-occupying lesion in right parietal region

neurological complications can occur due to metastatic
disease, occurring as paraneoplastic phenomena, or
treatment-induced neurological complication [6]. Some
of the paraneoplastic manifestations include degeneration of cerebellum, chorea, demyelinating polyradiculopathy, and myasthenia gravis. Therapeutic radiation
can lead to neurologic complications such as dropped
head syndrome, acute brachial plexopathy, and intracranial infarction. Furthermore, chemotherapy for Hodgkin
lymphoma may cause peripheral neuropathy and cerebral
infarction possibly due to drug-induced embolism [7].
Most research studies state the location of the lesion
to be supratentorial [8]. Several risk factors are responsible for disease relapse such as male gender, positive
family history, immunosuppressed state, and infection
with Epstein–Barr virus (EBV) [9]. In our case, tuberculosis was suspected since its coexistence with HL is well
reported, resulting from two potential processes: T-cell
dysfunction related to HL, and B-cell immune dysfunction resulting from HL therapy [10]. Tuberculosis and HL
can both involve the CNS, but to date, there is no literature that correlates an increased risk of CNS tuberculosis
with HL.
HL can affect CNS in several ways, including skull
contiguity, meningeal invasion, or through the hematogenous route, which is the most common route of spread
[11]. Some of the common manifestations of intracranial
involvement include cranial nerve palsies, with other
signs and symptoms such as headaches, papilledema,
paresis, seizures, and other neurological manifestations
[12]. In our case, the patient had a history of headaches
and an episode of loss of consciousness. Nodular sclerosis and mixed cellularity are the most commonly seen

histological subtypes of HL that occur in relapsed disease. Moreover, the presence of Reed–Sternberg cells
and co-expression of CD30 and CD15 antigens with
lack of CD20 and CD3 strongly support the diagnosis of
Hodgkin lymphoma [13]. The gold-standard diagnosis is
biopsy, which is essential for confirmation.
Due to the rare occurrence of this presentation and
insufficient data from clinical trials, no specific treatment guidelines have been established. Evidence suggests
a variety of treatment modalities, including radiotherapy
alone for isolated CNS involvement, or holocranial irradiation and combination chemotherapy. In the case of
meningeal disease, intrathecal methotrexate can be used
as well [4]. Other previously used modalities include stem
cell transplantation or surgery. CNS prophylaxis is not
routinely recommended in HL as more data are needed
to identify specific populations who could benefit from it
[14]. It is crucial for prompt screening and diagnosis of
debilitating complications that have low risk of suspicion
and paucity of evidence on treatment. Developing an
appropriate treatment strategy has been challenging due
to the short median survival of approximately 46 months
[6] after HL has been diagnosed. It has been observed
that prognosis is better in patients with disease limited to
CNS either initially or as relapse, compared with patients
with evidence of more than one site of relapse [15].

Conclusion
Relapsed Hodgkin lymphoma with CNS involvement is uncommon; therefore, space-occupying lesion
(SOL) should always be investigated and biopsy of such
lesions is gold standard to establish diagnosis. With
timely appropriate therapy, complete remission can be
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Fig. 2 Immunohistochemistry stained tissue biopsy of the lesion showing CD30(+), CD15(+), PAX5(+),CD3(−),CD20(−), and LCA(−)

achieved. However large-scale studies are still needed
to understand the presentation, survival, and treatment
options for patients with CNS-HL.
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